A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CheckMate 143
- Sponsors Bristol-Myers Squibb
- 16 Jul 2024 Status changed from active, no longer recruiting to completed.
- 01 Jul 2024 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 30 Jun 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.